1
1976
01
16
2019
02
08
0006-2944
13
2
1975
Jun
Biochemical medicine
Biochem Med
Formate assay in body fluids: application in methanol poisoning.
117-26
Makar
A B
AB
McMartin
K E
KE
Palese
M
M
Tephly
T R
TR
eng
MC_UU_12013/5
MRC
United Kingdom
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Biochem Med
0151424
0006-2944
0
Formates
142M471B3J
Carbon Dioxide
EC 1.2.-
Aldehyde Oxidoreductases
Y4S76JWI15
Methanol
IM
Aldehyde Oxidoreductases
metabolism
Animals
Body Fluids
analysis
Carbon Dioxide
blood
Formates
blood
poisoning
Haplorhini
Humans
Hydrogen-Ion Concentration
Kinetics
Methanol
blood
Methods
Pseudomonas
enzymology
1975
6
1
1975
6
1
0
1
1975
6
1
0
0
ppublish
1
10.1016/0006-2944(75)90147-7
2
1976
01
10
2019
06
12
1090-2104
66
4
1975
Oct
27
Biochemical and biophysical research communications
Biochem Biophys Res Commun
Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution.
1173-9
Bose
K S
KS
Sarma
R H
RH
eng
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
United States
Biochem Biophys Res Commun
0372516
0006-291X
0U46U6E8UK
NAD
53-59-8
NADP
IM
Biochem Pharmacol. 1975 Aug 15;24(16):1517-21
8
Fourier Analysis
Magnetic Resonance Spectroscopy
Models, Molecular
Molecular Conformation
NAD
analogs & derivatives
NADP
Structure-Activity Relationship
Temperature
1975
10
27
1975
10
27
0
1
1975
10
27
0
0
ppublish
2
0006-291X(75)90482-9
10.1016/0006-291x(75)90482-9
3
1976
01
10
2019
06
12
0006-291X
66
4
1975
Oct
27
Biochemical and biophysical research communications
Biochem Biophys Res Commun
Metal substitutions incarbonic anhydrase: a halide ion probe study.
1281-6
Smith
R J
RJ
Bryant
R G
RG
eng
Journal Article
Research Support, U.S. Gov't, P.H.S.
United States
Biochem Biophys Res Commun
0372516
0006-291X
00BH33GNGH
Cadmium
EC 4.2.1.1
Carbonic Anhydrases
FXS1BY2PGL
Mercury
J41CSQ7QDS
Zinc
IM
Animals
Binding Sites
Cadmium
Carbonic Anhydrases
metabolism
Cattle
Humans
Hydrogen-Ion Concentration
Magnetic Resonance Spectroscopy
Mercury
Protein Binding
Protein Conformation
Zinc
pharmacology
1975
10
27
1975
10
27
0
1
1975
10
27
0
0
ppublish
3
0006-291X(75)90498-2
10.1016/0006-291x(75)90498-2
4
1976
01
10
2019
06
12
1090-2104
66
4
1975
Oct
27
Biochemical and biophysical research communications
Biochem Biophys Res Commun
Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake.
1338-43
Wiesmann
U N
UN
DiDonato
S
S
Herschkowitz
N N
NN
eng
BB/C008219/1
Biotechnology and Biological Sciences Research Council
United Kingdom
G1100377
Medical Research Council
United Kingdom
G1100377
MRC
United Kingdom
Journal Article
United States
Biochem Biophys Res Commun
0372516
0006-291X
0
Dextrans
886U3H6UFF
Chloroquine
EC 3.1.6.-
Sulfatases
EC 3.1.6.8
Cerebroside-Sulfatase
EC 3.2.1.31
Glucuronidase
IM
Biological Transport
Cells, Cultured
Cerebroside-Sulfatase
metabolism
Chloroquine
pharmacology
Dextrans
metabolism
Fibroblasts
enzymology
metabolism
Glucuronidase
metabolism
Humans
Leukodystrophy, Metachromatic
enzymology
Lysosomes
drug effects
enzymology
Pinocytosis
drug effects
Skin
enzymology
Sulfatases
metabolism
1975
10
27
1975
10
27
0
1
1975
10
27
0
0
ppublish
4
0006-291X(75)90506-9
10.1016/0006-291x(75)90506-9
5
1976
01
10
2019
06
12
1090-2104
66
4
1975
Oct
27
Biochemical and biophysical research communications
Biochem Biophys Res Commun
Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin.
1349-56
Hendrickson
W A
WA
Ward
K B
KB
eng
Journal Article
United States
Biochem Biophys Res Commun
0372516
0006-291X
0
Hemerythrin
0
Metalloproteins
0
Muscle Proteins
IM
Animals
Cnidaria
Computers
Hemerythrin
Metalloproteins
Models, Molecular
Muscle Proteins
Protein Conformation
Species Specificity
1975
10
27
1975
10
27
0
1
1975
10
27
0
0
ppublish
5
0006-291X(75)90508-2
10.1016/0006-291x(75)90508-2
6
1976
01
10
2019
06
12
0006-291X
66
4
1975
Oct
27
Biochemical and biophysical research communications
Biochem Biophys Res Commun
Studies of oxygen binding energy to hemoglobin molecule.
1424-31
Chow
Y W
YW
Pietranico
R
R
Mukerji
A
A
eng
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
United States
Biochem Biophys Res Commun
0372516
0006-291X
0
Hemoglobins
0
Ligands
0
Oxyhemoglobins
3G0H8C9362
Cobalt
E1UOL152H7
Iron
S88TT14065
Oxygen
IM
Binding Sites
Cobalt
blood
Hemoglobins
Humans
Hydrogen-Ion Concentration
Iron
blood
Ligands
Mathematics
Oxygen
blood
Oxyhemoglobins
Protein Binding
Spectrum Analysis
1975
10
27
1975
10
27
0
1
1975
10
27
0
0
ppublish
6
0006-291X(75)90518-5
10.1016/0006-291x(75)90518-5
7
1976
01
26
2020
02
25
1873-2968
24
16
1975
Aug
15
Biochemical pharmacology
Biochem Pharmacol
Maturation of the adrenal medulla--IV. Effects of morphine.
1469-74
Anderson
T R
TR
Slotkin
T A
TA
eng
MC_U147585819
MRC
United Kingdom
MC_UU_12011/1
MRC
United Kingdom
MC_UP_A620_1014
MRC
United Kingdom
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
England
Biochem Pharmacol
0101032
0006-2952
0
Catecholamines
76I7G6D29C
Morphine
818U2PZ2EH
Metaraminol
EC 1.14.16.2
Tyrosine 3-Monooxygenase
EC 1.14.17.1
Dopamine beta-Hydroxylase
YKH834O4BH
Epinephrine
IM
Adrenal Medulla
enzymology
growth & development
metabolism
Aging
Animals
Animals, Newborn
Body Weight
drug effects
Catecholamines
metabolism
Dopamine beta-Hydroxylase
metabolism
Epinephrine
metabolism
Female
Humans
In Vitro Techniques
Maternal-Fetal Exchange
Metaraminol
metabolism
Morphine
pharmacology
Morphine Dependence
metabolism
Pregnancy
Rats
Tyrosine 3-Monooxygenase
metabolism
1975
8
15
1975
8
15
0
1
1975
8
15
0
0
ppublish
7
0006-2952(75)90020-9
10.1016/0006-2952(75)90020-9
Br J Gen Pract. 1999 Oct;49(447):823-8
10885091
J Gastroenterol Hepatol. 2000 Oct;15(10):1093-9
11106086
Ann Intern Med. 2001 Jul 3;135(1):68-9
11434754
J Viral Hepat. 2001 Sep;8(5):358-66
11555193
BJOG. 2002 Mar;109(3):227-35
11950176
Drug Saf. 2002;25(5):323-44
12020172
Am J Med. 2002 Oct 15;113(6):506-15
12427501
J Altern Complement Med. 2003 Feb;9(1):161-8
12676044
Psychosomatics. 2003 Jul-Aug;44(4):271-82
12832592
Aliment Pharmacol Ther. 2003 Sep 1;18(5):451-71
12950418
Dig Dis Sci. 2003 Oct;48(10):1925-8
14627335
Cochrane Database Syst Rev. 2004;(1):CD002286
14973986
Mycoses. 2004 Apr;47(3-4):87-92
15078424
Planta Med. 2004 Apr;70(4):293-8
15095142
J Herb Pharmacother. 2004;4(1):49-67
15273078
J Herb Pharmacother. 2003;3(2):69-90
15277068
J Herb Pharmacother. 2003;3(1):121-33
15277076
J Herb Pharmacother. 2002;2(3):49-72
15277090
J Herb Pharmacother. 2002;2(1):71-85
15277109
J Herb Pharmacother. 2004;4(2):63-78
15364646
Expert Opin Pharmacother. 2004 Dec;5(12):2485-501
15571467
Drug Saf. 2005;28(4):319-32
15783241
Obstet Gynecol. 2005 Apr;105(4):849-56
15802416
J Herb Pharmacother. 2004;4(3):63-83
15829470
Obes Rev. 2005 May;6(2):93-111
15836459
Drug Saf. 2005;28(5):387-400
15853441
J Herb Pharmacother. 2004;4(4):61-90
15927926
Semin Arthritis Rheum. 2005 Jun;34(6):773-84
15942912
Expert Opin Drug Saf. 2005 Jul;4(4):779-94
16011454
J Herb Pharmacother. 2005;5(1):79-93
16093238
Complement Ther Med. 2005 Dec;13(4):279-90
16338199
Phytomedicine. 2006 May;13(5):371-7
16487688
J Herb Pharmacother. 2005;5(3):119-43
16520304
J Herb Pharmacother. 2005;5(4):71-114
16635970
Drug Saf. 2006;29(6):523-35
16752934
Mov Disord. 2006 Oct;21(10):1709-15
16830309
Eur Respir J. 2006 Aug;28(2):330-8
16880367
J Herb Pharmacother. 2006;6(1):89-126
17135164
J Herb Pharmacother. 2006;6(2):101-22
17182489
J Herb Pharmacother. 2006;6(3-4):135-59
17317655
Int J Toxicol. 2007;26 Suppl 1:3-106
17365137
Br J Psychiatry. 2007 May;190:379-84
17470951
Sleep Med Rev. 2007 Jun;11(3):209-30
17517355
J Herb Pharmacother. 2007;7(1):99-113
17594991
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004559
17943819
Can J Physiol Pharmacol. 2007 Sep;85(9):837-47
18066129
World J Gastroenterol. 2008 Jan 21;14(3):454-62
18200670
Can J Clin Pharmacol. 2008 Winter;15(1):e66-73
18204101
J Herb Pharmacother. 2007;7(2):91-143
18285310
J Clin Epidemiol. 1991;44(11):1271-8
1834807
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005288
18425916
Drug Saf. 2008;31(6):469-84
18484782
Cell Mol Neurobiol. 2009 Feb;29(1):17-25
18584321
J Herb Pharmacother. 2007;7(3-4):143-77
18928139
J Herb Pharmacother. 2007;7(3-4):279-323
18928148
Evid Based Complement Alternat Med. 2009 Mar;6(1):99-105
18955223
Am J Obstet Gynecol. 2008 Nov;199(5):455-66
18984078
Phytother Res. 2009 Apr;23(4):447-59
19086008
J Soc Integr Oncol. 2009 Spring;7(2):73-80
19476742
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006568
19588398
Drug Saf. 2009;32(8):637-47
19591529
Curr Gastroenterol Rep. 2009 Aug;11(4):317-24
19615308
World J Gastroenterol. 2009 Oct 21;15(39):4886-95
19842218
Rev Recent Clin Trials. 2009 Sep;4(3):168-74
20028328
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006556
20091597
Cardiovasc Hematol Agents Med Chem. 2010 Apr;8(2):113-27
20370653
Menopause. 2011 Apr;18(4):366-75
21228727
Planta Med. 2011 Jul;77(11):1149-60
21259185
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD002948
21328257
Maturitas. 2011 Sep;70(1):37-41
21782365
J Psychiatr Res. 2011 Nov;45(11):1518-24
21820672
BMC Complement Altern Med. 2011 Aug 28;11:72
21871125
J Diet Suppl. 2010 Sep;7(3):283-302
22432518
J Diet Suppl. 2010 Dec;7(4):351-413
22432564
J Diet Suppl. 2011 Mar;8(1):58-114
22432635
J Diet Suppl. 2011 Jun;8(2):189-238
22432689
J Diet Suppl. 2011 Sep;8(3):311-30
22432729
J Diet Suppl. 2009;6(1):54-90
22435354
J Diet Suppl. 2009;6(2):162-200
22435415
J Diet Suppl. 2010 Jun;7(2):179-215
22435615
8
1976
01
26
2020
02
25
1873-2968
24
16
1975
Aug
15
Biochemical pharmacology
Biochem Pharmacol
Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase.
1517-21
Moroi
K
K
Sato
T
T
eng
SF19107
Biotechnology and Biological Sciences Research Council
United Kingdom
Comparative Study
Journal Article
Published Erratum
England
Biochem Pharmacol
0101032
0006-2952
0
Metals
0
Phospholipids
0
Proteins
34237V843T
Isocarboxazid
4Z8Y51M438
Procaine
EC 3.1.-
Esterases
EC 3.5.-
Amidohydrolases
IM
Biochem Biophys Res Commun. 1975 Oct 27;66(4):1173-9
2
Amidohydrolases
metabolism
Animals
Esterases
metabolism
Hydrogen-Ion Concentration
In Vitro Techniques
Isocarboxazid
metabolism
Kinetics
Male
Metals
pharmacology
Microsomes, Liver
enzymology
Phospholipids
metabolism
Procaine
metabolism
Proteins
metabolism
Rats
Subcellular Fractions
enzymology
Temperature
1975
8
15
1975
8
15
0
1
1975
8
15
0
0
ppublish
8
0006-2952(75)90029-5
10.1016/0006-2952(75)90029-5
Nature. 2001 May 31;411(6837):599-603
11385576
Gastroenterology. 2003 Jul;125(1):47-57
12851870
Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):525-39
15157825
Gastroenterology. 2004 Oct;127(4):1051-7
15480983
N Engl J Med. 2004 Nov 11;351(20):2069-79
15537905
Nat Med. 2005 Apr;11(4):383-4
15812518
Int J Colorectal Dis. 2006 Dec;21(8):747-53
16228179
World J Gastroenterol. 2006 Apr 7;12(13):1991-9
16610046
Am J Gastroenterol. 2006 Jul;101(7):1559-68
16863561
Science. 2006 Dec 1;314(5804):1461-3
17068223
Int J Immunogenet. 2007 Jun;34(3):181-91
17504508
Nat Rev Genet. 2008 Jan;9(1):9-14
17968351
Nat Genet. 2008 Aug;40(8):955-62
18587394
Inflamm Bowel Dis. 2008 Nov;14(11):1469-82
18618634
Gut. 2008 Sep;57(9):1294-6
18719139
Nature. 2008 Nov 13;456(7219):259-63
18849966
Annu Rev Genomics Hum Genet. 2009;10:89-116
19453248
Inflamm Bowel Dis. 2009 Nov;15(11):1643-55
19462429
Nat Immunol. 2009 Oct;10(10):1073-80
19701189
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15813-8
19805227
Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):513-34
19817673
Nat Immunol. 2010 Jan;11(1):55-62
19898471
Curr Gastroenterol Rep. 2009 Dec;11(6):481-7
19903424
Nat Med. 2010 Jan;16(1):90-7
19966812
Inflamm Bowel Dis. 2010 Jul;16(7):1108-17
20024904
Am J Gastroenterol. 2010 Aug;105(8):1811-9
20197757
Curr Opin Gastroenterol. 2010 Jul;26(4):327-31
20445446
J Immunol. 2010 Jun 15;184(12):7247-56
20483763
Inflamm Bowel Dis. 2011 Jan;17(1):346-61
20839313
Nat Genet. 2010 Dec;42(12):1118-25
21102463
Gastroenterology. 1989 Apr;96(4):1016-20
2925048
Gut. 1988 Jul;29(7):990-6
3396969
Nature. 1996 Feb 29;379(6568):821-3
8587604
Gastroenterology. 1996 Sep;111(3):597-603
8780562
Gut. 1996 Nov;39(5):690-7
9014768
9
1976
01
23
2019
06
23
0006-2952
24
17
1975
Sep
01
Biochemical pharmacology
Biochem Pharmacol
Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo.
1569-72
Marniemi
J
J
Parkki
M G
MG
eng
Journal Article
Research Support, U.S. Gov't, P.H.S.
England
Biochem Pharmacol
0101032
0006-2952
0
Carrier Proteins
0
Epoxy Compounds
0
Styrenes
56-49-5
Methylcholanthrene
EC 2.5.1.18
Glutathione Transferase
GAN16C9B8O
Glutathione
YQE403BP4D
Phenobarbital
IM
Animals
Carrier Proteins
metabolism
Epoxy Compounds
metabolism
pharmacology
Glutathione
pharmacology
Glutathione Transferase
metabolism
Hydrogen-Ion Concentration
Liver
enzymology
Male
Methylcholanthrene
pharmacology
Phenobarbital
pharmacology
Rats
Stimulation, Chemical
Styrenes
pharmacology
1975
9
1
1975
9
1
0
1
1975
9
1
0
0
ppublish
9
0006-2952(75)90080-5
10.1016/0006-2952(75)90080-5
10
1976
01
23
2020
03
03
1873-2968
24
17
1975
Sep
01
Biochemical pharmacology
Biochem Pharmacol
Digitoxin metabolism by rat liver microsomes.
1639-41
Schmoldt
A
A
Benthe
H F
HF
Haberland
G
G
eng
K01 AG044439
AG
NIA NIH HHS
United States
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
143-62-4
Digitoxigenin
53-59-8
NADP
E90NZP2L9U
Digitoxin
IM
Animals
Chromatography, Thin Layer
Digitoxigenin
metabolism
Digitoxin
metabolism
Hydroxylation
In Vitro Techniques
Male
Microsomes, Liver
metabolism
NADP
metabolism
Rats
Time Factors
1975
9
1
1975
9
1
0
1
1975
9
1
0
0
ppublish
10
0006-2952(75)90094-5
11
1976
01
23
2020
02
25
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Identification of adenylate cyclase-coupled beta-adrenergic receptors with radiolabeled beta-adrenergic antagonists.
1651-8
Lefkowitz
R J
RJ
eng
Journal Article
Research Support, U.S. Gov't, P.H.S.
England
Biochem Pharmacol
0101032
0006-2952
0
Adrenergic beta-Antagonists
0
Catecholamines
0
Receptors, Adrenergic
10028-17-8
Tritium
877K5MQ27W
Alprenolol
9Y8NXQ24VQ
Propranolol
EC 4.6.1.1
Adenylyl Cyclases
L628TT009W
Isoproterenol
IM
Adenylyl Cyclases
blood
metabolism
Adrenergic beta-Antagonists
pharmacology
Alprenolol
blood
Animals
Anura
Binding Sites
Catecholamines
pharmacology
Cattle
Cell Membrane
enzymology
Eels
Erythrocytes
enzymology
Guinea Pigs
In Vitro Techniques
Isoproterenol
pharmacology
Kinetics
Propranolol
pharmacology
Receptors, Adrenergic
drug effects
Stereoisomerism
Tritium
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
11
0006-2952(75)90001-5
10.1016/0006-2952(75)90001-5
J Am Coll Cardiol. 2002 Jul 3;40(1):142-8
12103268
Postgrad Med J. 2005 Jul;81(957):442-7
15998820
Eur Heart J. 2006 Feb;27(3):344-50
16223744
Heart. 2006 Apr;92(4):559-68
16537784
Europace. 2006 Sep;8(9):746-837
16935866
Eur Heart J. 2007 Sep;28(18):2256-95
17726042
J Cardiovasc Electrophysiol. 2008 Jan;19(1):48-55
17916139
QJM. 2009 Jul;102(7):485-90
19474111
Eur Heart J. 2009 Nov;30(21):2631-71
19713422
Ann Intern Med. 1997 Jun 15;126(12):989-96
9182479
12
1976
01
23
2020
02
25
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells.
1659-62
Stein
J M
JM
eng
G1002528
Medical Research Council
United Kingdom
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
0
Adrenergic alpha-Antagonists
0
Adrenergic beta-Antagonists
0
Phosphorus Radioisotopes
0TTZ664R7Z
Phenoxybenzamine
27YLU75U4W
Phosphorus
8L70Q75FXE
Adenosine Triphosphate
9Y8NXQ24VQ
Propranolol
EC 1.13.12.-
Luciferases
EC 2.7.1.1
Hexokinase
YKH834O4BH
Epinephrine
IM
Adenosine Triphosphate
biosynthesis
metabolism
Adipose Tissue
drug effects
metabolism
Adrenergic alpha-Antagonists
pharmacology
Adrenergic beta-Antagonists
pharmacology
Animals
Epinephrine
pharmacology
Hexokinase
pharmacology
In Vitro Techniques
Luciferases
pharmacology
Male
Oxygen Consumption
drug effects
Phenoxybenzamine
pharmacology
Phosphorus
metabolism
Phosphorus Radioisotopes
Propranolol
pharmacology
Rats
Time Factors
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
12
0006-2952(75)90002-7
10.1016/0006-2952(75)90002-7
Int J Qual Health Care. 2007 Feb;19(1):50-5
17172600
Nurse Educ Pract. 2008 Sep;8(5):299-301
18692016
BMJ. 2009 Apr 21;338:b1555
19383750
BMJ. 2009 May 12;338:b1900
19435768
BMJ. 2011 Feb 03;342:c6646
21292716
BMJ. 2011 Sep 13;343:d5672
21914758
BMJ Qual Saf. 2012 Mar;21(3):234-8
22282817
Clin Med (Lond). 2012 Dec;12(6):520-5
23342404
BMJ Qual Saf. 2013 Aug;22(8):613-7
23661281
13
1976
01
23
2019
06
23
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
1701-5
Järvisalo
J
J
Saris
N E
NE
eng
G9901400
Medical Research Council
United Kingdom
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
2001-95-8
Valinomycin
8L70Q75FXE
Adenosine Triphosphate
9Y8NXQ24VQ
Propranolol
EC 3.6.1.-
Adenosine Triphosphatases
RRU6GY95IS
Nigericin
RWP5GA015D
Potassium
IM
Adenosine Triphosphatases
metabolism
Adenosine Triphosphate
pharmacology
Animals
Hydrogen-Ion Concentration
In Vitro Techniques
Mitochondria
drug effects
Mitochondria, Liver
enzymology
metabolism
Mitochondrial Swelling
drug effects
Nigericin
pharmacology
Oxidative Phosphorylation
drug effects
Oxygen Consumption
drug effects
Potassium
pharmacology
Propranolol
pharmacology
Rats
Time Factors
Valinomycin
pharmacology
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
13
0006-2952(75)90009-X
10.1016/0006-2952(75)90009-x
14
1976
01
23
2020
02
25
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Malathion A and B esterases of mouse liver-I.
1713-7
Bhagwat
V M
VM
Ramachandran
B V
BV
eng
G0100165
Medical Research Council
United Kingdom
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
0
Metals
0
Sulfhydryl Compounds
EC 3.1.-
Esterases
U5N7SU872W
Malathion
IM
Animals
Drug Stability
Esterases
analysis
antagonists & inhibitors
isolation & purification
Female
Hydrogen-Ion Concentration
Liver
enzymology
ultrastructure
Malathion
metabolism
Male
Metals
pharmacology
Mice
Sex Factors
Sulfhydryl Compounds
pharmacology
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
14
0006-2952(75)90011-8
10.1016/0006-2952(75)90011-8
Nature. 2003 Jan 2;421(6918):37-42
12511946
Proc Biol Sci. 2003 Sep 22;270(1527):1887-92
14561301
Nature. 2004 Jan 8;427(6970):145-8
14712274
Nature. 2006 Jan 12;439(7073):161-7
16407945
15
1976
01
23
2020
02
25
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Increase in acetyl CoA synthetase activity after phenobarbital treatment.
1725-7
Akamatsu
N
N
Nakajima
H
H
Ono
M
M
Miura
Y
Y
eng
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
0
Proteins
98600C0908
Cycloheximide
EC 2.6.1.16
Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)
EC 2.7.-
Phosphotransferases
EC 3.1.1.6
Acetylesterase
EC 6.2.1.-
Coenzyme A Ligases
EC 6.2.1.1
Acetate-CoA Ligase
N08U5BOQ1K
Glucosamine
V956696549
Acetylglucosamine
YQE403BP4D
Phenobarbital
IM
Acetate-CoA Ligase
metabolism
Acetylesterase
metabolism
Acetylglucosamine
Animals
Coenzyme A Ligases
metabolism
Cycloheximide
pharmacology
Glucosamine
Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)
metabolism
Liver
drug effects
enzymology
Male
Phenobarbital
pharmacology
Phosphotransferases
metabolism
Proteins
metabolism
Rats
Stimulation, Chemical
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
15
0006-2952(75)90013-1
10.1016/0006-2952(75)90013-1
Clin Med (Lond). 2005 Jul-Aug;5(4):344-8
16138488
Arch Dis Child. 2007 Jul;92(7):573-5
17588971
Arch Dis Child. 2007 Dec;92(12):1143
18032643
Pediatrics. 2010 Nov;126(5):851-5
20956413
J Health Serv Res Policy. 2011 Apr;16(2):75-80
21389060
BMJ. 2011 Apr 18;342:d2421
21502273
Clin Med (Lond). 2011 Oct;11(5):420-1
22034695
Bull Hist Med. 1998 Summer;72(2):246-78
9628051
16
1976
01
23
2020
02
25
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines.
1731-3
Turner
A J
AJ
Hick
P E
PE
eng
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
0
Biogenic Amines
0
Pyrimidines
53-59-8
NADP
EC 1.2.-
Aldehyde Oxidoreductases
X77S6GMS36
Homovanillic Acid
IM
Aldehyde Oxidoreductases
antagonists & inhibitors
Animals
Biogenic Amines
metabolism
pharmacology
Brain
enzymology
Homovanillic Acid
pharmacology
In Vitro Techniques
Kinetics
NADP
Pyrimidines
pharmacology
Sheep
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
16
0006-2952(75)90016-7
10.1016/0006-2952(75)90016-7
J Clin Endocrinol Metab. 2000 Feb;85(2):637-44
10690869
NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25
14768652
Endocr Rev. 2004 Apr;25(2):309-40
15082524
J Endocrinol Invest. 2006 Apr;29(4):298-302
16699294
N Engl J Med. 2007 Feb 8;356(6):601-10
17287480
Endocr Pract. 2008 Apr;14(3):279-84
18463033
Endocr Pract. 2009 Jul-Aug;15 Suppl 1:1-20
19632967
Endocrine. 2010 Feb;37(1):40-6
19882253
J Clin Endocrinol Metab. 2010 Sep;95(9):4106-13
20823463
Endocrine. 2011 Aug;40(1):80-3
21547511
Endocrine. 2011 Aug;40(1):134-6
21562920
Br J Surg. 2011 Oct;98(10):1383-91
21618498
Horm Metab Res. 2011 Dec;43(13):962-9
22048862
BMJ. 2012 May 28;344:e3502
22645185
17
1976
01
23
2020
03
04
0006-2952
24
18
1975
Sep
15
Biochemical pharmacology
Biochem Pharmacol
Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat.
1739-42
Renaud
B
B
Buda
M
M
Lewis
B D
BD
Pujol
J F
JF
eng
HERU1
CSO_
Chief Scientist Office
United Kingdom
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
0
Catecholamines
0
Tryptamines
EC 1.14.16.2
Tyrosine 3-Monooxygenase
W2QY253O8S
5,6-Dihydroxytryptamine
IM
5,6-Dihydroxytryptamine
administration & dosage
pharmacology
Animals
Brain
enzymology
Catecholamines
physiology
Cerebral Cortex
enzymology
Cisterna Magna
Corpus Striatum
enzymology
In Vitro Techniques
Injections
Male
Neurons
enzymology
Rats
Rats, Inbred Strains
Stimulation, Chemical
Substantia Nigra
enzymology
Time Factors
Tryptamines
pharmacology
Tyrosine 3-Monooxygenase
metabolism
1975
9
15
1975
9
15
0
1
1975
9
15
0
0
ppublish
17
0006-2952(75)90018-0
10.1016/0006-2952(75)90018-0
BMJ. 2010 Apr 20;340:c2016
20406861
18
1976
01
29
2019
06
23
0006-2952
24
20
1975
Oct
15
Biochemical pharmacology
Biochem Pharmacol
Inhibition of aldehyde reductase isoenzymes in human and rat brain.
1865-9
Ris
M M
MM
Deitrich
R A
RA
Von Wartburg
J P
JP
eng
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
England
Biochem Pharmacol
0101032
0006-2952
0
Anticonvulsants
0
Barbiturates
0
Hydantoins
0
Isoenzymes
0
Succinimides
0U46U6E8UK
NAD
53-59-8
NADP
C8I4BVN78E
Glutethimide
EC 1.2.-
Aldehyde Oxidoreductases
IM
Aldehyde Oxidoreductases
antagonists & inhibitors
Animals
Anticonvulsants
pharmacology
Barbiturates
pharmacology
Brain
enzymology
Glutethimide
pharmacology
Humans
Hydantoins
pharmacology
In Vitro Techniques
Isoenzymes
antagonists & inhibitors
Kinetics
NAD
metabolism
NADP
pharmacology
Rats
Succinimides
pharmacology
1975
10
15
1975
10
15
0
1
1975
10
15
0
0
ppublish
18
0006-2952(75)90405-0
10.1016/0006-2952(75)90405-0
19
1976
01
29
2020
02
25
0006-2952
24
20
1975
Oct
15
Biochemical pharmacology
Biochem Pharmacol
Antidepressant drugs affect dopamine uptake.
1896-7
Halaris
A E
AE
Belendiuk
K T
KT
Freedman
D X
DX
eng
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
England
Biochem Pharmacol
0101032
0006-2952
0
Antidepressive Agents
0
Central Nervous System Stimulants
VTD58H1Z2X
Dopamine
IM
Animals
Antidepressive Agents
pharmacology
Brain
drug effects
metabolism
Central Nervous System Stimulants
pharmacology
Depression, Chemical
Dopamine
metabolism
In Vitro Techniques
Male
Rats
1975
10
15
1975
10
15
0
1
1975
10
15
0
0
ppublish
19
0006-2952(75)90412-8
10.1016/0006-2952(75)90412-8
JAMA. 2001 Jun 13;285(22):2871-9
11401608
Med Care. 2001 Aug;39(8 Suppl 2):II2-45
11583120
Health Serv Manage Res. 2002 May;15(2):126-37
12028801
Qual Saf Health Care. 2003 Dec;12(6):458-64
14645763
J Am Soc Nephrol. 2004 Mar;15(3):754-60
14978178
Lancet. 2004 Apr 3;363(9415):1147-54
15064036
BMJ. 2005 Apr 2;330(7494):781-3
15802723
J Am Coll Cardiol. 2005 Oct 4;46(7):1236-41
16198837
Milbank Q. 2005;83(4):691-729
16279964
JAMA. 2006 Jan 18;295(3):324-7
16418469
N Engl J Med. 2006 Nov 30;355(22):2308-20
17101617
J Eval Clin Pract. 2007 Apr;13(2):161-8
17378860
N Engl J Med. 2007 Aug 9;357(6):608-13
17687138
Qual Saf Health Care. 2007 Oct;16(5):387-99
17913782
BMJ. 2008 Jun 28;336(7659):1491-4
18577559
BMJ. 2008 Aug 13;337:a957
18703659
JAMA. 2008 Dec 24;300(24):2913-5
19109120
Clin Med (Lond). 2009 Apr;9(2):140-4
19435119
BMJ. 2009 Nov 19;339:b4809
19926689
BMJ. 2009 Nov 19;339:b4811
19926690
BMJ. 2010 Mar 31;340:c1234
20360220
BMJ. 2010 Apr 20;340:c2016
20406861
BMJ. 2010 Apr 23;340:c2153
20418546
N Engl J Med. 2010 Jul 1;363(1):45-53
20463332
BMJ. 2010 Aug 13;341:c4078
20709715
N Engl J Med. 2010 Dec 23;363(26):2477-81
21142528
J Am Soc Nephrol. 2011 Feb;22(2):225-34
21289212
BMJ. 2011 Feb 03;342:d199
21292720
Clin Med (Lond). 2010 Dec;10(6):537-9
21413472
Nephron Clin Pract. 2011;119(1):c10-7; discussion c17
21659780
Kidney Int. 2011 Nov;80(10):1021-34
21775971
Implement Sci. 2011 Oct 24;6:119
22024188
BMJ. 2012 Mar 01;344:e1001
22381521
Methods Inf Med. 2012;51(3):189-98
22476327
Ann Intern Med. 1998 Feb 15;128(4):289-92
9471932
Int J Qual Health Care. 1998 Oct;10(5):443-7
9828034
20
1976
01
29
2020
02
25
0006-2952
24
20
1975
Oct
15
Biochemical pharmacology
Biochem Pharmacol
Aggregation of blood platelets by adrenaline and its uptake.
1903-4
Barthel
W
W
Markwardt
F
F
eng
Journal Article
England
Biochem Pharmacol
0101032
0006-2952
436O5HM03C
Dihydroergotamine
8NA5SWF92O
Lysergic Acid Diethylamide
YKH834O4BH
Epinephrine
IM
Animals
Blood Platelets
metabolism
Dihydroergotamine
pharmacology
Drug Interactions
Epinephrine
blood
pharmacology
In Vitro Techniques
Lysergic Acid Diethylamide
pharmacology
Platelet Aggregation
drug effects
Rabbits
1975
10
15
1975
10
15
0
1
1975
10
15
0
0
ppublish
20
0006-2952(75)90415-3
10.1016/0006-2952(75)90415-3
Int J Qual Health Care. 2008 Feb;20(1):22-30
18073269
Qual Health Res. 2008 Mar;18(3):380-90
18235161
N Engl J Med. 2009 Jan 29;360(5):491-9
19144931
Med Educ. 1998 May;32(3):239-43
9743776
21
1976
01
26
2017
03
22
0004-4172
25
9
1975
Sep
Arzneimittel-Forschung
Arzneimittelforschung
[Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)].
1352-4
(--)-alpha-Bisabolol has a primary antipeptic action depending on dosage, which is not caused by an alteration of the pH-value. The proteolytic activity of pepsin is reduced by 50 percent through addition of bisabolol in the ratio of 1/0.5. The antipeptic action of bisabolol only occurs in case of direct contact. In case of a previous contact with the substrate, the inhibiting effect is lost.
Isaac
O
O
Thiemer
K
K
ger
English Abstract
Journal Article
Biochemische Untersuchungen von Kamilleninhaltsstoffen. III. In-vitro-Versuche über die antipeptische Wirkung des (-)-alpha-Bisabolols
Germany
Arzneimittelforschung
0372660
0004-4172
0
Hemoglobins
0
Sesquiterpenes
42HK56048U
Tyrosine
5V2JDO056X
Trichloroacetic Acid
EC 3.4.23.1
Pepsin A
IM
Dose-Response Relationship, Drug
Hemoglobins
metabolism
Hydrogen-Ion Concentration
In Vitro Techniques
Methods
Pepsin A
antagonists & inhibitors
metabolism
Plants, Medicinal
Sesquiterpenes
pharmacology
Spectrophotometry, Ultraviolet
Trichloroacetic Acid
Tyrosine
metabolism
1975
9
1
1975
9
1
0
1
1975
9
1
0
0
ppublish
21
22
1976
01
26
2020
02
25
0004-4172
25
9
1975
Sep
Arzneimittel-Forschung
Arzneimittelforschung
[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities].
1369-79
A report is given on the recent discovery of outstanding immunological properties in BA 1 [N-(2-cyanoethylene)-urea] having a (low) molecular mass M = 111.104. Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1.7 percent), results in a recovery rate of 40 percent without hyperglycemia and, in one test, of 80 percent with hyperglycemia. Under otherwise unchanged conditions the reference substance ifosfamide (IF) -- a further development of cyclophosphamide -- applied without hyperglycemia in its most efficient dosage of 47 percent LD50 (150 mg kg) brought about a recovery rate of 25 percent at a lethality of 18 percent. (Contrary to BA 1, 250-min hyperglycemia caused no further improvement of the recovery rate.) However this comparison is characterized by the fact that both substances exhibit two quite different (complementary) mechanisms of action. Leucocyte counts made after application of the said cancerostatics and dosages have shown a pronounced stimulation with BA 1 and with ifosfamide, the known suppression in the post-therapeutic interval usually found with standard cancerostatics. In combination with the cited plaque test for BA 1, blood pictures then allow conclusions on the immunity status. Since IF can be taken as one of the most efficient cancerostatics--there is no other chemotherapeutic known up to now that has a more significant effect on the DS carcinosarcoma in rats -- these findings are of special importance. Finally, the total amount of leucocytes and lymphocytes as well as their time behaviour was determined from the blood picture of tumour-free rats after i.v. application of BA 1. The thus obtained numerical values clearly show that further research work on the prophylactic use of this substance seems to be necessary and very promising.
Ardenne
M
M
Reitnauer
P G
PG
ger
Comparative Study
English Abstract
Journal Article
Nachweis krebshemmender Eigenschaften einer stark immunstimulierenden Verbindung kleiner Molekülmasse. Versuche am immunlabilen DS-Karzinosarkom im Vergleich mit Ifosfamid. Stimulierung der körpereigenen Abwehr über etwa 20 Tage durch BA 1, einen N-(2-Cyanthylen)-harnstoff. Neue prophylaktische Möglichkeiten
Germany
Arzneimittelforschung
0372660
0004-4172
0
Antineoplastic Agents
8N3DW7272P
Cyclophosphamide
8W8T17847W
Urea
UM20QQM95Y
Ifosfamide
IM
Animals
Antineoplastic Agents
pharmacology
therapeutic use
Carcinosarcoma
drug therapy
Cyclophosphamide
analogs & derivatives
Drug Evaluation, Preclinical
Drug Tolerance
Erythrocyte Count
Hydrogen-Ion Concentration
Hyperglycemia
Ifosfamide
pharmacology
therapeutic use
Immunity
drug effects
Immunosuppression
Lethal Dose 50
Leukocyte Count
Male
Mice
Neoplasms, Experimental
drug therapy
Rats
Stimulation, Chemical
Time Factors
Urea
analogs & derivatives
pharmacology
therapeutic use
1975
9
1
1975
9
1
0
1
1975
9
1
0
0
ppublish
22
Crit Care Med. 2006 Jul;34(7):1913-7
16715038
Crit Care. 2007;11(2):R31
17331245
J Am Soc Nephrol. 2010 Feb;21(2):345-52
20019168
Am J Kidney Dis. 2010 Oct;56(4):651-60
20673605
Blood Purif. 2010;30(2):120-6
20714143
Nephrol Dial Transplant. 2011 Jul;26(7):2161-8
21148028
Am J Kidney Dis. 2011 Feb;57(2):228-34
21195518
Clin J Am Soc Nephrol. 2012 Apr;7(4):533-40
22362062
QJM. 2012 Aug;105(8):729-40
22408153
Clin J Am Soc Nephrol. 2012 May;7(5):712-9
22422536
QJM. 2013 Apr;106(4):323-32
23345468
J R Coll Physicians Edinb. 2013;43(1):37-8
23516690
23
1976
01
26
2020
02
25
0004-4172
25
9
1975
Sep
Arzneimittel-Forschung
Arzneimittelforschung
Effect of etafenone on total and regional myocardial blood flow.
1400-3
The distribution of blood flow to the subendocardial, medium and subepicardial layers of the left ventricular free wall was studied in anaesthetized dogs under normoxic (A), hypoxic (B) conditions and under pharmacologically induced (etafenone) coronary vasodilation (C). Regional myocardial blood flow was determined by means of the particle distribution method. In normoxia a transmural gradient of flow was observed, with the subendocardial layers receiving a significantly higher flow rate compared with the subepicardial layers. In hypoxia induced vasodilation this transmural gradient of flow was persistent. In contrast a marked redistribution of regional flow was observed under pharmacologically induced vasodilation. The transmural gradient decreased. In contrast to some findings these experiments demonstrate that a considerable vasodilatory capacity exists in all layers of the myocardium and can be utilized by drugs. The differences observed for the intramural distribution pattern of flow under hypoxia and drug induced vasodilation support the hypothesis that this pattern reflects corresponding gradients of regional myocardial metabolism.
Flohr
H
H
Breull
W
W
eng
G0700399
Medical Research Council
United Kingdom
Journal Article
Germany
Arzneimittelforschung
0372660
0004-4172
0
Propiophenones
0
Vasodilator Agents
142M471B3J
Carbon Dioxide
S88TT14065
Oxygen
IM
Animals
Blood Pressure
drug effects
Carbon Dioxide
blood
Cardiac Output
drug effects
Coronary Circulation
drug effects
Coronary Vessels
drug effects
Dogs
Heart Rate
drug effects
Heart Septum
Heart Ventricles
Hydrogen-Ion Concentration
Hypoxia
physiopathology
Oxygen
blood
Propiophenones
pharmacology
Vasodilator Agents
pharmacology
1975
9
1
1975
9
1
0
1
1975
9
1
0
0
ppublish
23
J Appl Psychol. 2001 Aug;86(4):730-40
11519656
South Med J. 2005 May;98(5):528-32
15954509
J Crit Care. 2008 Jun;23(2):167-72
18538207
Med Educ. 2009 Jan;43(1):50-7
19140997
Clin Med (Lond). 2009 Oct;9(5):417-20
19886098